Tags

Type your tag names separated by a space and hit enter

Effects of HMG-CoA reductase inhibitor on hemostasis.
Int J Cardiol. 2000 Oct; 76(1):23-32.IJ

Abstract

Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy have demonstrated improvement in coronary atherosclerosis progression and reduction in risk of cardiovascular events. However, improvement in cardiovascular end-points is incompletely explained by the baseline or treated LDL cholesterol level. The beneficial effects of statins on clinical events may involve nonlipid mechanisms that modify hemostasis. Local activation of platelets and thrombus formation adjacent to atheromatous plaques, especially where ruptured or eroded, are now recognized to be of pathophysiological importance in the acute and chronic clinical expression of coronary heart disease. Thus, favorable effects of statins on hemostasis may be relevant to decreasing or delaying the progression and clinical manifestations of atherosclerosis.

Authors+Show Affiliations

Division of Cardiology, Heart Center, Gachon Medical School, 1198 Kuwol-dong, Namdong-gu, 405-760, Inchon, South Korea. kwangk@ghil.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11121593

Citation

Koh, K K.. "Effects of HMG-CoA Reductase Inhibitor On Hemostasis." International Journal of Cardiology, vol. 76, no. 1, 2000, pp. 23-32.
Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol. 2000;76(1):23-32.
Koh, K. K. (2000). Effects of HMG-CoA reductase inhibitor on hemostasis. International Journal of Cardiology, 76(1), 23-32.
Koh KK. Effects of HMG-CoA Reductase Inhibitor On Hemostasis. Int J Cardiol. 2000;76(1):23-32. PubMed PMID: 11121593.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of HMG-CoA reductase inhibitor on hemostasis. A1 - Koh,K K, PY - 2000/12/21/pubmed PY - 2001/3/3/medline PY - 2000/12/21/entrez SP - 23 EP - 32 JF - International journal of cardiology JO - Int. J. Cardiol. VL - 76 IS - 1 N2 - Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy have demonstrated improvement in coronary atherosclerosis progression and reduction in risk of cardiovascular events. However, improvement in cardiovascular end-points is incompletely explained by the baseline or treated LDL cholesterol level. The beneficial effects of statins on clinical events may involve nonlipid mechanisms that modify hemostasis. Local activation of platelets and thrombus formation adjacent to atheromatous plaques, especially where ruptured or eroded, are now recognized to be of pathophysiological importance in the acute and chronic clinical expression of coronary heart disease. Thus, favorable effects of statins on hemostasis may be relevant to decreasing or delaying the progression and clinical manifestations of atherosclerosis. SN - 0167-5273 UR - https://www.unboundmedicine.com/medline/citation/11121593/Effects_of_HMG_CoA_reductase_inhibitor_on_hemostasis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0167-5273(00)00325-9 DB - PRIME DP - Unbound Medicine ER -